We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
-1.06%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$136M
AUM Growth
-$26.8M
Cap. Flow
-$22.4M
Cap. Flow %
-16.5%
Top 10 Hldgs %
67.25%
Holding
41
New
7
Increased
7
Reduced
12
Closed
6

Top Buys

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$4.21M
2
FDMT icon
4D Molecular Therapeutics
FDMT
+$2.04M
3
ARGX icon
argenx
ARGX
+$1.66M
4
ALKS icon
Alkermes
ALKS
+$863K
5
KURA icon
Kura Oncology
KURA
+$796K

Top Sells

Rank Stock Value
1
VRDN icon
Viridian Therapeutics
VRDN
+$7.33M
2
MRSN
Mersana Therapeutics
MRSN
+$5M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$4.51M
4
BCAB icon
BioAtla
BCAB
+$4.13M
5
KROS icon
Keros Therapeutics
KROS
+$3.86M

Sector Composition

Rank Sector Weight
1 Healthcare 94.65%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APLS
1
DELISTED
Apellis Pharmaceuticals
APLS
$19.2M 14.12%
290,500
+73,000
+34% +$4.21M
WHWK
2
Whitehawk Therapeutics
WHWK
$196M
$13.4M 9.86%
1,849,402
– –
TERN
3
DELISTED
Terns Pharmaceuticals
TERN
$13M 9.59%
1,099,309
-691
-0.1% -$6.6K
CBAY
4
DELISTED
Cymabay Therapeutics
CBAY
$7.66M 5.64%
878,500
-136,500
-13% -$1.09M
VTYX
5
DELISTED
Ventyx Biosciences
VTYX
$6.98M 5.15%
208,500
-82,000
-28% -$3.19M
SNDX icon
6
Syndax Pharmaceuticals
SNDX
$1.7B
$6.97M 5.13%
330,000
+5,386
+2% +$134K
KURA icon
7
Kura Oncology
KURA
$816M
$6.91M 5.09%
565,257
+63,757
+13% +$796K
ISEE
8
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$6.82M 5.03%
280,500
-80,000
-22% -$1.75M
UTHR icon
9
United Therapeutics
UTHR
$25.7B
$5.26M 3.88%
23,500
-9,500
-29% -$2.34M
RCKT icon
10
Rocket Pharmaceuticals
RCKT
$372M
$5.1M 3.76%
298,000
+38,000
+15% +$744K
BLU
11
DELISTED
BELLUS Health Inc.
BLU
$4.55M 3.35%
632,500
– –
SRPT icon
12
Sarepta Therapeutics
SRPT
$1.68B
$4.52M 3.33%
32,770
-34,730
-51% -$4.51M
PCVX icon
13
Vaxcyte
PCVX
$7.73B
$4.52M 3.33%
120,500
-24,000
-17% -$1.02M
CLDX icon
14
Celldex Therapeutics
CLDX
$2.96B
$4.37M 3.22%
121,500
+6,500
+6% +$280K
VRDN icon
15
Viridian Therapeutics
VRDN
$2.13B
$4.27M 3.15%
168,000
-228,500
-58% -$7.33M
ARGX icon
16
argenx
ARGX
$52B
$3.57M 2.63%
9,594
+4,494
+88% +$1.66M
GHRS icon
17
GH Research
GHRS
$1.93B
$1.94M 1.43%
243,250
– –
FDMT icon
18
4D Molecular Therapeutics
FDMT
$527M
$1.8M 1.33%
+104,753
New +$2.04M
ACRS icon
19
Aclaris Therapeutics
ACRS
$772M
$986K 0.73%
121,840
-133,160
-52% -$1.69M
IOVA icon
20
Iovance Biotherapeutics
IOVA
$1.93B
$939K 0.69%
153,639
– –
ALKS icon
21
Alkermes
ALKS
$8.31B
$893K 0.66%
+31,689
New +$863K
EYPT icon
22
EyePoint Inc
EYPT
$1.04B
$892K 0.66%
303,396
– –
PMVP icon
23
PMV Pharmaceuticals
PMVP
$59.7M
$737K 0.54%
154,471
– –
RZLT icon
24
Rezolute
RZLT
$473M
$703K 0.52%
366,204
-53,796
-13% -$121K
ELVN icon
25
Enliven Therapeutics
ELVN
$4.15B
$678K 0.5%
30,979
+19,853
+178% +$404K
1
2

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return

Acuta Capital Partners's Q1 2023 Portfolio in Review

As of Q1 2023, Acuta Capital Partners held 41 positions worth $136M, down 16% from $163M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Acuta Capital Partners withdrew a net $22.4M in Q1 2023, closing 6 positions and reducing 12 holdings. Its most notable exit was BioAtla, an estimated $4.13M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 100% a quarter earlier.

Against the trend, Acuta Capital Partners opened a new position in 4D Molecular Therapeutics worth $1.8M.

  • Acuta Capital Partners's largest Q1 2023 buy was 4D Molecular Therapeutics: 104,753 shares worth $1.8M.
  • Acuta Capital Partners added most to Apellis Pharmaceuticals in Q1 2023, an estimated $4.21M increase.
  • Acuta Capital Partners's biggest Q1 2023 reduction was Viridian Therapeutics, cutting an estimated $7.33M.
  • Acuta Capital Partners fully exited BioAtla in Q1 2023, selling an estimated $4.13M.
  • Acuta Capital Partners's ten largest holdings make up 67% of its $136M portfolio in Q1 2023.
  • Acuta Capital Partners opened 7 new positions and closed 6 in Q1 2023.
  • Acuta Capital Partners's portfolio value fell 16% quarter-over-quarter to $136M.

Based on Acuta Capital Partners's 13F filing for Q1 2023, filed 15 May 2023.